Comparison of the Analgesic Effects of Continuous Versus Single-Shot Serratus Posterior Superior Intercostal Plane Block in Arthroscopic Shoulder Surgery

NCT ID: NCT06826846

Last Updated: 2026-01-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-01
• Study Completion Date: 2025-10-10

Brief Summary

Patients undergoing arthroscopic shoulder surgery often experience moderate to severe postoperative pain. Various medical treatments are employed to provide analgesia for these patients. The advancement of regional anesthesia techniques has made possible to both reduce the use of narcotic analgesics and provide long-term pain management benefits.

The Serratus Posterior Superior Intercostal Plane Block (SPSIPB) was first described in 2023 by Serkan Tulgar et al. Cadaveric studies and dermatomal analyses in patients have demonstrated its ability to provide analgesia in the back, neck, shoulder, axilla, and lateral thoracic regions.

Even though patients undergoing shoulder surgery benefit from the block; once the duration of a single-shot block wears off, they may experience severe pain again. The aim of this study is to investigate the analgesic effects of a single-shot SPSIPB compared to continuous infusion provided by placing a catheter in this region.

The hypothesis of this study: In arthroscopic shoulder surgery, the continuous application of the serratus posterior superior intercostal plane block using a catheter will result in lower pain scores, reduced opioid consumption, and improved patient satisfaction compared to single-shot application.

Conditions

Arthroscopic Shoulder Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

Group 1: This patient group will not undergo any regional block

Group Type: NO_INTERVENTION

No interventions assigned to this group

Group 2: Patients who will receive a single-shot serratus posterior superior plane block

Group Type: ACTIVE_COMPARATOR

Serratus posterior superior intercostal plane block (single-shot)

Intervention Type: OTHER

30 mL of 0.25% bupivacaine will be injected as single-shot block 20 mins prior to surgery

Group 3: Patients who will receive a continuous SPSIB with catheter

Group Type: ACTIVE_COMPARATOR

Serratus posterior superior intercostal plane block (catheter)

Intervention Type: OTHER

In addition to administration of 30 mL of 0.25% bupivacaine prior to surgery, a catheter will be placed in the area to administer bolus of 1 mg/kg of 0.25% bupivacaine every 8 hours postoperatively.

Interventions

Serratus posterior superior intercostal plane block (single-shot)

30 mL of 0.25% bupivacaine will be injected as single-shot block 20 mins prior to surgery

Intervention Type: OTHER

Serratus posterior superior intercostal plane block (catheter)

In addition to administration of 30 mL of 0.25% bupivacaine prior to surgery, a catheter will be placed in the area to administer bolus of 1 mg/kg of 0.25% bupivacaine every 8 hours postoperatively.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Aged between 18-80 years
• No bleeding diathesis
• Classified as ASA I-II-III

Exclusion Criteria

• Patients who do not provide consent
• Patients with coagulopathy
• History of allergy or intoxication to local anesthetic agents
• Patients with advanced organ failure
• History of neuropathic disease
• Patients with mental retardation
• Presence of infection at the injection site
• Conditions in which regional anesthesia is contraindicated
• Pediatric patients and those over 80 years of age
• Pregnant patients

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Goztepe Prof Dr Suleyman Yalcın City Hospital

OTHER

Sponsor Role: lead

Responsible Party

ILKER YALCIN

Anesthesiology and Reanimation Resident, M.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Senem Koruk

Role: STUDY_DIRECTOR

Goztepe Prof Dr Suleyman Yalcın City Hospital

Locations

Goztepe Suleyman Yalcin City Hospital

Istanbul, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

AOSPS001

Identifier Type: -

Identifier Source: org_study_id